Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

Condition:   HPV 16+ Recurrent or Metastatic Cancer Interventions:   Biological: CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16;   Biological: Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16 Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   PapiVax Biotech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials